Fall is finally here, and with it comes the onset of Flu Season. Flu is a difficult illness for everyone, but for cancer patients, it can be devastating. It is especially confusing in this year which continues to challenge everyone with the uncertainty of COVID-19 and its variants.
In this issue of LRG Science: based on current studies, this article asserts the belief that placebos do not benefit patients with advanced disease.
Dr. Jason Sicklick of Moores Cancer Center at UC San Diego dedicated his new research lab to the memory of GISTer Merak Melikian Hatounian.
The welfare of our members and staff is of utmost importance to us and due to ongoing pandemic, we have decided to take the precaution of postponing our GIST DO IT Walk which was scheduled for October 2nd.
Our GEM Donor Program has a group of new donors that will help the LRG continue the work we do with patients and #GISTresearch. Our thanks go out to our newest GEM!
A recent study in Cancer Genetics, International initiative for a curated SDHB variant database improving the diagnosis of hereditary paraganglioma and pheochromocytoma, is important for GIST patients who carry a germline SDHB mutation
Australian GIST Advocates Overcome Payer Obstacles Concerning Qinlock. 4th line drug approval was approved! GISTer Sarah McGoram shares the news.
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Martha Hunt shares her story.
This issue of LRG Science presents six case studies as evidence that the practice of biomarker/mutational testing early in a GIST patient's journey is a critical path to the most effective treatment. Each patient was diagnosed with GIST, but did not receive mutational testing early enough to avoid suffering adverse side effects and wasting money on unnecessary, costly drugs.
Two new studies were published in July and August 2021 focusing on SDH-deficient tumor models and how location can affect GIST tumor profiles and drug sensitivity.